Analyst Price Target is $16.73
▲ +49.81% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $16.73, with a high forecast of $36.00 and a low forecast of $7.00. The average price target represents a 49.81% upside from the last price of $11.17.
Current Consensus is
The current consensus among 15 contributing investment analysts is to hold stock in Editas Medicine. This Hold consensus rating has held steady for over two years.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.